Chinese AI agent firms trail US but aim to catch up amid OpenAI advances
Chinese AI agent firms face weaker digital infrastructure and budget constraints but are accelerating adoption to compete with US rivals like OpenAI.
Chinese AI agent firms are trailing their US counterparts in commercialization, according to a report by the China International Capital Corporation (CICC). The research highlights that overseas AI agent makers, led by companies like OpenAI, have significantly higher orders and revenues—exceeding Chinese firms by an order of magnitude in 2024-2025. This disparity stems from stronger digital infrastructure and higher IT budgets among US corporate clients.
Key Findings:
- Market Penetration: The US had 100 million AI agent users in 2024, representing a 40% adoption rate, while China, with 250 million users, lagged at 17.7%.
- Challenges for Chinese Firms: Weak digital infrastructure and macroeconomic pressures have constrained budgets for AI adoption in China.
- OpenAI’s Latest Push: On Friday, OpenAI launched a new ChatGPT agent capable of handling complex workflows end-to-end. CEO Sam Altman described it as a "real 'feel the AGI' moment", referencing artificial general intelligence.
Industry Outlook:
Despite the gap, Chinese firms are accelerating adoption to compete globally. The rise of AI agents—software that autonomously plans and executes tasks—has become the next frontier after large language models in the generative AI race.
"The macro environment has impacted digitalization budgets, but Chinese companies are catching up," the CICC report noted. The competition is set to intensify as OpenAI and other US firms continue to raise the bar.
Related News
IBM Launches New AI Agents for Oracle Fusion Applications
IBM introduces three new AI agents for Oracle Fusion Cloud Applications, automating enterprise tasks and enhancing operational efficiency.
Heidi Health secures 65M Series B funding for AI medical scribe
Heidi Health raised 65 million in Series B funding led by Steve Cohens Point72 Private Investments to expand its AI medical scribe platform.
About the Author

David Chen
AI Startup Analyst
Senior analyst focusing on AI startup ecosystem with 11 years of venture capital and startup analysis experience. Former member of Sequoia Capital AI investment team, now independent analyst writing AI startup and investment analysis articles for Forbes, Harvard Business Review and other publications.